GlassScriptPhysician profile
Aryel Nicoleau
NPI 1093880957
$31,675.21
in general payments reported to CMS, 2019-2025
73 companies · $4,773 in 2025
The $4,773 reported for 2025 was more than what 97% of Internal Medicine providers received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $4,063 · 2020: $3,269 · 2021: $5,132 · 2022: $4,035 · 2023: $5,146 · 2024: $5,257 · 2025: $4,773.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $15K · Education: $323.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $14,852.60 |
| Education | $323.01 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $2,971.23 | 2019-2025 | Farxiga, Airsupra, Breztri |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $2,143.80 | 2020-2025 | Caplyta |
| Abbvie INC. | $1,981.82 | 2019-2025 | |
| Lilly USA, LLC | $1,589.29 | 2019-2025 | Mounjaro, Jardiance, Zepbound |
| Novo Nordisk INC | $1,564.93 | 2019-2025 | Ozempic, Rybelsus, Wegovy |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $1,548.48 | 2019-2025 | Xifaxan, Trulance, Cycloset |
| Amgen INC. | $1,301.36 | 2019-2025 | Repatha, Evenity, Prolia |
| Sanofi-Aventis U.S. LLC | $1,296.58 | 2019-2025 | |
| Scilex Pharmaceuticals INC. | $1,068.61 | 2019-2025 | Ztlido |
| Astellas Pharma US INC | $1,061.95 | 2019-2024 | Veozah, Myrbetriq |
| Janssen Pharmaceuticals, INC | $1,047.15 | 2019-2024 | Xarelto |
| Pfizer INC. | $1,014.38 | 2019-2025 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $990.41 | 2019-2024 | Jardiance, Tradjenta, Glyxambi |
| Novartis Pharmaceuticals Corporation | $812.97 | 2019-2025 | |
| Merck Sharp & Dohme LLC | $784.07 | 2019-2025 | Verquvo, Capvaxive, Gardasil |
Show all 70 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Ardelyx, INC. | $783.24 | 2022-2025 | Ibsrela |
| Glaxosmithkline, LLC. | $768.25 | 2019-2025 | Trelegy Ellipta |
| Teva Pharmaceuticals USA, INC. | $739.11 | 2020-2025 | Austedo Xr, Austedo Xr, Austedo |
| Bayer Healthcare Pharmaceuticals INC. | $707.37 | 2021-2025 | |
| Ironwood Pharmaceuticals, INC | $663.08 | 2019-2024 | Linzess |
| Abbott Laboratories | $602.12 | 2023-2025 | Freestyle Libre 3 |
| Allergan, INC. | $414.20 | 2019-2020 | |
| Akebia Therapeutics INC | $410.86 | 2019-2024 | Auryxia |
| Smith+Nephew, INC. | $396.86 | 2019-2025 | Collagenase Santyl |
| Kowa Pharmaceuticals America, INC. | $299.54 | 2021-2025 | Zoryve |
| Mannkind Corporation | $273.29 | 2019-2024 | |
| Alkermes, INC. | $244.04 | 2023 | Lybalvi |
| Otsuka America Pharmaceutical, INC. | $238.99 | 2022-2024 | Rexulti |
| Esperion Therapeutics, INC. | $237.41 | 2020-2025 | Nexletol |
| Horizon Therapeutics Plc | $222.18 | 2019-2021 | |
| Ani Pharmaceuticals, INC. | $209.10 | 2025 | Purified Cortrophin Gel |
| Nestle Healthcare Nutrition INC. | $205.80 | 2021-2022 | |
| Sumitomo Pharma America, INC. | $181.43 | 2023-2025 | Gemtesa, Myfembree |
| Eisai INC. | $179.85 | 2023-2025 | |
| Phathom Pharmaceuticals, INC. | $168.54 | 2025 | Voquezna |
| Biohaven Pharmaceuticals, INC. | $166.41 | 2020-2021 | |
| Amarin Pharma, INC. | $158.84 | 2019-2022 | |
| Xeris Pharmaceuticals, INC. | $149.37 | 2025 | Gvoke Hypopen, Recorlev |
| Arbor Pharmaceuticals, INC. | $148.71 | 2019-2020 | |
| Takeda Pharmaceuticals U.S.A., INC. | $141.69 | 2019-2020 | |
| Cequr Corporation | $134.30 | 2025 | Cequr Simplicity |
| Opko Pharmaceuticals, LLC | $125.84 | 2024-2025 | Rayaldee |
| Exact Sciences Corporation | $122.27 | 2024-2025 | Cologuard Collection Kit, The Cologuard Plus Collection Kit |
| Corium, LLC | $121.53 | 2023 | Adlarity |
| E.R. Squibb & Sons, L.L.C. | $116.89 | 2019-2025 | Eliquis |
| Avanir Pharmaceuticals, INC. | $111.86 | 2020-2022 | |
| Corcept Therapeutics | $110.32 | 2024-2025 | Korlym |
| Lifescan, INC. | $108.02 | 2019-2022 | |
| Sunovion Pharmaceuticals INC. | $94.14 | 2020-2022 | |
| Axsome Therapeutics, INC. | $89.45 | 2024-2025 | Auvelity |
| Scpharmaceuticals INC. | $76.20 | 2025 | |
| Daiichi Sankyo INC. | $74.09 | 2022-2023 | Injectafer |
| Idorsia Pharmaceuticals US INC | $68.57 | 2023 | Quviviq |
| Hikma Pharmaceuticals USA | $53.46 | 2019-2021 | |
| Shield Therapeutics INC | $48.67 | 2023-2025 | Accrufer |
| Azurity Pharmaceuticals, INC. | $40.84 | 2023-2024 | Horizant, Edarbyclor |
| Gilead Sciences, INC. | $32.27 | 2021 | |
| Impel Pharmaceuticals INC. | $24.92 | 2022 | |
| Paratek Pharmaceuticals, INC. | $24.12 | 2025 | Nuzyra |
| Biohaven Pharmaceutical Holding Company LTD. | $23.52 | 2022 | |
| Lundbeck LLC | $23.28 | 2023 | Rexulti |
| Nevro Corp. | $23.14 | 2021 | |
| Bridgebio Pharma, INC. | $21.44 | 2025 | Attruby |
| Insulet Corporation | $20.83 | 2024 | Omnipod |
| Biogen, INC. | $20.83 | 2021 | |
| Vifor Pharma, INC. | $19.27 | 2020 | |
| Aimmune Therapeutics, INC. | $16.79 | 2024 | |
| Eyevance Pharmaceuticals LLC | $15.30 | 2021 | |
| Vanda Pharmaceuticals INC. | $14.22 | 2024 | Fanapt |
| Assertio Therapeutics, INC. | $11.52 | 2020 |
3 companies reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Aryel Nicoleau listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.